Marshall Wace LLP lifted its position in shares of Regenxbio Inc (NASDAQ:RGNX) by 74.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 356,786 shares of the biotechnology company’s stock after purchasing an additional 151,737 shares during the quarter. Marshall Wace LLP owned approximately 1.00% of Regenxbio worth $26,937,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently made changes to their positions in the company. Riverhead Capital Management LLC boosted its stake in Regenxbio by 137.5% in the 3rd quarter. Riverhead Capital Management LLC now owns 1,900 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 1,100 shares in the last quarter. Meadow Creek Investment Management LLC acquired a new stake in Regenxbio in the 2nd quarter valued at $141,000. Russell Investments Group Ltd. acquired a new stake in Regenxbio in the 2nd quarter valued at $157,000. Glen Harbor Capital Management LLC acquired a new stake in Regenxbio in the 2nd quarter valued at $171,000. Finally, SG Americas Securities LLC acquired a new stake in Regenxbio in the 2nd quarter valued at $179,000. 79.08% of the stock is currently owned by institutional investors.
Several brokerages recently commented on RGNX. Raymond James boosted their price target on Regenxbio from $76.00 to $96.00 and gave the company an “outperform” rating in a research note on Friday, September 7th. TheStreet raised Regenxbio from a “d+” rating to a “c” rating in a research note on Monday, September 17th. BidaskClub raised Regenxbio from a “hold” rating to a “buy” rating in a research note on Saturday, November 3rd. Zacks Investment Research upgraded Regenxbio from a “hold” rating to a “buy” rating and set a $78.00 price objective for the company in a research report on Wednesday, November 7th. Finally, Barclays lifted their price objective on Regenxbio from $48.00 to $83.00 and gave the company an “overweight” rating in a research report on Monday, August 13th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $77.81.
In other news, CFO Vittal Vasista sold 7,500 shares of the business’s stock in a transaction on Monday, September 17th. The stock was sold at an average price of $74.86, for a total transaction of $561,450.00. Following the completion of the sale, the chief financial officer now owns 120,722 shares in the company, valued at $9,037,248.92. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Kenneth T. Mills sold 7,510 shares of the business’s stock in a transaction on Monday, October 15th. The stock was sold at an average price of $59.35, for a total value of $445,718.50. Following the sale, the chief executive officer now owns 331,710 shares of the company’s stock, valued at approximately $19,686,988.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 448,954 shares of company stock valued at $28,902,916. Corporate insiders own 16.90% of the company’s stock.
Shares of RGNX opened at $52.44 on Friday. Regenxbio Inc has a 52-week low of $23.25 and a 52-week high of $85.10. The firm has a market capitalization of $2.01 billion, a price-to-earnings ratio of 27.00, a price-to-earnings-growth ratio of 8.29 and a beta of -0.53.
Regenxbio (NASDAQ:RGNX) last issued its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.86) by $0.30. Regenxbio had a return on equity of 22.52% and a net margin of 44.30%. The firm had revenue of $5.31 million during the quarter. On average, equities research analysts expect that Regenxbio Inc will post 2.23 earnings per share for the current year.
Regenxbio Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Featured Story: What is the NASDAQ?
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.